Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison

Table 3 Safety profiles of hepatitis C virus-infected patients receiving direct-acting antivirals therapy in Penghu prison

n (%)	Total	Sporadic HCV therapy in outpatient clinics (January 1, 2019 - December 31, 2019)	Campaign of HCV micro-elimination with simplified pan-genotypic SOF/VEL regimen (January 1, 2020 - March 31, 2020)
n	303	91	212
Treatment discontinuation other than released or transferred	0 (0.0)	0 (0.0)	0 (0.0)
Serious adverse events	0 (0.0)	0 (0.0)	0 (0.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)
Adverse events	7 (2.3)	4 (4.3)	3 (1.4)
Fatigue	0 (0.0)	0 (0.0)	0 (0.0)
Pruritus	2 (0.7)	0 (0.0)	2 (0.9)
Rash	3 (1.0)	3 (3.2)	0 (0.0)
Nausea	0 (0.0)	0 (0.0)	0 (0.0)
Anorexia	0 (0.0)	0 (0.0)	0 (0.0)
Constipation	0 (0.0)	0 (0.0)	0 (0.0)
Dizziness	0 (0.0)	0 (0.0)	0 (0.0)
Insomnia	0 (0.0)	0 (0.0)	0 (0.0)
Headache	1 (0.3)	0 (0.0)	1 (0.5)
Others	1 (0.3)	1 (1.0)	0 (0.0)
Grade 3 or 4 laboratory abnormalities
Total blood bilirubin	0 (0.0)	0 (0.0)	0 (0.0)
Alanine aminotransferase	0 (0.0)	0 (0.0)	0 (0.0)

DAA: Directly-acting antivirals; HCV: Hepatitis C virus; VEL: Velpatasvir; SOF: Sofosbuvir.